MIDROC Investment Group has introduced seven new pediatric intravenous (IV) fluid products, marking a significant milestone in improving healthcare services for infants and young children in Ethiopia.
Health experts say the initiative reflects MIDROC’s strong commitment to corporate social responsibility by addressing critical healthcare needs and expanding access to essential pediatric medical supplies.
The seven pediatric IV fluids have been developed and manufactured by Pharmacure PLC, MIDROC Investment Group’s leading pharmaceutical company, as part of its efforts to strengthen the country’s healthcare system.
Speaking at the launch ceremony, State Minister of Health Frehiwot Abebe praised MIDROC Investment Group for its consistent contribution to community development, stating that the company deserves recognition for its unwavering commitment to supporting the nation’s health sector and improving the well-being of citizens.
Pharmacure PLC General Manager Solomon W/Amanuel, on his part, said the company’s founding vision has always been to make a meaningful contribution to Ethiopia’s healthcare sector.
He noted that the introduction of the seven pediatric IV fluid products demonstrates Pharmacure’s dedication to producing high-quality, life-saving medicines and supporting the country’s growing demand for locally manufactured pharmaceutical products.
